SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Cash Equivalents
SCI Pharmtech Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Cash Equivalents
NT$448.1m
|
CAGR 3-Years
152%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Cash Equivalents
NT$69.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cash Equivalents
NT$4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cash Equivalents
NT$596.9m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
12%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Cash Equivalents?
Cash Equivalents
448.1m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Cash Equivalents amounts to 448.1m TWD.
What is SCI Pharmtech Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
7%
Over the last year, the Cash Equivalents growth was 1 200%. The average annual Cash Equivalents growth rates for SCI Pharmtech Inc have been 152% over the past three years , 6% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet